MHRA authorization of Dupixent (dupilumab) marks a significant step forward as the UK ...
MHRA approves Dupixent (dupilumab) as the first targeted biologic for uncontrolled COPD in the UK, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. NICE and SMC to review for reimbursement.
Reference News
MHRA authorization of Dupixent (dupilumab) marks a significant step forward as the UK ...
MHRA approves Dupixent (dupilumab) as the first targeted biologic for uncontrolled COPD in the UK, based on phase 3 studies showing significant reduction in exacerbations and improved lung function. NICE and SMC to review for reimbursement.
Sanofi/Regeneron's Dupixent approved by MHRA to treat uncontrolled COPD - PMLiVE
Sanofi and Regeneron’s Dupixent approved by MHRA as add-on treatment for uncontrolled COPD in UK, reducing exacerbations and improving lung function.